<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Dr. Pollyea on Indications for Anti-CD33 Therapy in AML

Written by OncLive on July 19, 2021

Daniel Pollyea, MD, MS, associate professor of medicine/hematology, and the clinical director of Leukemia Services at the University of Colorado School of Medicine, discusses indications for anti-CD33 therapy in the treatment of patients with acute myeloid leukemia (AML).

Topics: Press Coverage

Comments